| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.06 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.27 | 0.06 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.07 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.07 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.079 | 0.07 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.052 | 0.07 |